Download PDF
Exp Clin Endocrinol Diabetes 2009; 117(2): 72-77
DOI: 10.1055/s-2008-1078710
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Nitrosylated Proteins in Monocytes as a new Marker of Oxidative-Nitrosative Stress in Diabetic Subjects with Macroangiopathy

U. Julius 1 , V. R. Drel 2 , J. Gräßler 1 , I. G. Obrosova 2
  • 1Medical Clinic III, University Hospital, Dresden, Germany
  • 2Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA
Further Information

Publication History

received 12.02.2008 first decision 11.03.2008

accepted 28.04.2008

Publication Date:
25 August 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Peroxynitrite plays an important role in the pathogenesis of diabetic complications. Nitrosylated protein expression in peripheral blood monocytes reflects intracellular peroxynitrite injury, and thus could be a marker of higher diagnostic and prognostic value than plasma nitrotyrosine level. The purpose of this pilot study was to assess if peripheral blood monocytes of diabetic subjects accumulate nitrosylated proteins, and if nitrosylated protein expression correlates with blood glucose control, variables of lipid profile, C-reactive protein concentration (a marker of inflammation), and differs in patients with and without diabetic macrovascular and microvascular complications.

Methods: Nitrosylated protein expression in peripheral blood monocytes (Western blot analysis) was assessed in 31 subjects with diabetes mellitus (29 Type 2, 2 Type 1; 20 males, 11 females; mean age 66 years). The presence of microangiopathy was defined by retinopathy, albumin excretion, and/or neuropathy, and macroangiopathy by carotid plaques, a history of myocardial infarction, and/or stroke.

Results: Diabetic subjects accumulated significant amounts of nitrosylated proteins in peripheral blood monocytes. Nitrosylated protein expression positively correlated with body weight, blood glucose, HbA1C, and plasma C-reactive protein concentrations in the whole cohort as well as in subjects with diabetic macroangiopathy.

Conclusions: Monocyte nitrosylated protein expression is a new biomarker of metabolic control and inflammation in diabetic subjects with macroangiopathy. A more detailed assessment of diabetic microvascular complications in a larger group of patients is needed to determine if this variable can be employed as a biomarker of the presence, severity, and progression of diabetic neuropathy, retinopathy, and nephropathy.

Key words

nitrosylated proteins - diabetes mellitus - plasma glucose - HbA1C - lipids

References

  • 1 Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease.  Physiol Rev. 2007;  87 315-424
    CrossrefPubMedGoogle Scholar
  • 2 Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Duzer JH Van, Williams W, Salzman AL, Groves JT. Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst.  Mol Med. 2002;  8 571-580
    PubMedGoogle Scholar
  • 3 Virag L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention.  Toxicol Lett. 2003;  140–141 113-124
    PubMedGoogle Scholar
  • 4 Pacher P, Obrosova IG, Mabley JG, Szabo C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies.  Curr Med Chem. 2005;  12 267-275
    PubMedGoogle Scholar
  • 5 Obrosova IG, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens MJ, Yorek MA. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.  Diabetes. 2005;  54 234-242
    CrossrefPubMedGoogle Scholar
  • 6 Kowluru RA, Kanwar M, Kennedy A. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries.  Exp Diabetes Res. 2007;  2007 21976
    PubMedGoogle Scholar
  • 7 Drel VR, Pacher P, Stevens MJ, Obrosova IG. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.  Free Radic Biol Med. 2006;  40 1454-1465
    CrossrefPubMedGoogle Scholar
  • 8 Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, Szabo C. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst.  FASEB J. 2005;  19 401-403
    PubMedGoogle Scholar
  • 9 Drel VR, Mashtalir N, Ilnytska O, Shin J, Li F, Lyzogubov VV, Obrosova IG. The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity.  Diabetes. 2006;  55 3335-3343
    CrossrefPubMedGoogle Scholar
  • 10 Vareniuk I, Pavlov IA, Drel VR, Lyzogubov VV, Ilnytska O, Bell SR, Tibrewala J, Groves JT, Obrosova IG. Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice.  Exp Neurol. 2007;  205 425-436
    CrossrefPubMedGoogle Scholar
  • 11 Drel VR, Pacher P, Vareniuk I, Pavlov I, Ilnytska O, Lyzogubov VV, Tibrewala J, Groves JT, Obrosova IG. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice.  Eur J Pharmacol. 2007;  569 48-58
    CrossrefPubMedGoogle Scholar
  • 12 Obrosova IG, Ilnytska O, Lyzogubov VV, Pavlov IA, Mashtalir N, Nadler JL, Drel VR. High-fat diet induced neuropathy of pre-diabetes and obesity: effects of „healthy” diet and aldose reductase inhibition.  Diabetes. 2007;  56 2598-2608
    CrossrefPubMedGoogle Scholar
  • 13 Drel VR, Pacher P, Vareniuk I, Pavlov IA, Ilnytska O, Lyzogubov VV, Bell SR, Groves JT, Obrosova IG. Evaluation of the peroxynitrite decomposition catalyst Fe(III)tetra-mesitylporphyrin octasulfonate (FeTMPS) on peripheral neuropathy in a mouse model of Type 1 diabetes.  Int J Mol Med. 2007;  20 783-792
    PubMedGoogle Scholar
  • 14 Obrosova IG, Drel VR, Oltman CL, Mashtalir N, Tibrewala J, Groves JT, Yorek MA. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats.  Am J Physiol Endocrinol Metab. 2007;  , published online
    PubMedGoogle Scholar
  • 15 Oltman CL, Richou LL, Davidson EP, Coppey LJ, Lund DD, Yorek MA. Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats.  Am J Physiol Heart Circ Physiol. 2006;  291 H1780-H1787
    CrossrefPubMedGoogle Scholar
  • 16 Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress.  Diabetologia. 2001;  44 834-838
    CrossrefPubMedGoogle Scholar
  • 17 Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E. Role of hyperglycemia in nitrotyrosine postprandial generation.  Diabetes Care. 2002;  25 1439-1443
    CrossrefPubMedGoogle Scholar
  • 18 Ceriello A, Assaloni R, Da Ros R, Maier A, Quagliaro L, Piconi L, Esposito K, Giugliano D. Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients.  Diabetologia. 2004;  47 1535-1540
    CrossrefPubMedGoogle Scholar
  • 19 Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A. Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity.  Circulation. 2002;  106 2680-2686
    CrossrefPubMedGoogle Scholar
  • 20 Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P. Myocardial cell death in human diabetes.  Circ Res. 2000;  87 1123-1132
    PubMedGoogle Scholar
  • 21 Thuraisingham RC, Nott CA, Dodd SM, Yaqoob MM. Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy.  Kidney Int. 2000;  57 1968-1972
    CrossrefPubMedGoogle Scholar
  • 22 Nangle MR, Cotter MA, Cameron NE. Effects of the peroxynitrite decomposition catalyst, FeTMPyP, on function of corpus cavernosum from diabetic mice.  Eur J Pharmacol. 2004;  502 143-148
    CrossrefPubMedGoogle Scholar
  • 23 Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Kern TS, Ball S, Berkowitz BA. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes.  Diabetologia. 2007;  50 1987-1996
    CrossrefPubMedGoogle Scholar
  • 24 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications.  Biotechnology. 1992;  24 145-149
    PubMedGoogle Scholar
  • 25 Ceriello A, Piconi L, Esposito K, Giugliano D. Telmisartan shows an equivalent effect of vitamin C in further improving endothelial dysfunction after glycemia normalization in type 1 diabetes.  Diabetes Care. 2007;  30 1694-1698
    CrossrefPubMedGoogle Scholar
  • 26 Assaloni R, Da Ros R, Quagliaro L, Piconi L, Maier A, Zuodar G, Motz E, Ceriello A. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients.  Diabetologia. 2005;  48 1919-1924
    CrossrefPubMedGoogle Scholar
  • 27 Ceriello A, Lush CW, Darsow T, Piconi L, Corgnali M, Nanayakkara N, Frias JP, Maggs D. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.  Diabetes Metab Res Rev. 2007;  , published online
    PubMedGoogle Scholar
  • 28 Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, Esposito K, Giugliano D. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.  Circulation. 2005;  111 2518-2524
    CrossrefPubMedGoogle Scholar
  • 29 Johnson JB, Summer W, Cutler RG, Martin B, Hyun DH, Dixit VD, Pearson M, Nassar M, Tellejohan R, Maudsley S, Carlson O, John S, Laub DR, Mattson MP. Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma.  Free Radic Biol Med. 2007;  42 665-674
    CrossrefPubMedGoogle Scholar
  • 30 Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats.  Diabetes. 2004;  53 3233-3238
    CrossrefPubMedGoogle Scholar
  • 31 Ihnat MA, Thorpe JE, Kamat CD, Szabo C, Green DE, Warnke LA, Lacza Z, Cselenyak A, Ross K, Shakir S, Piconi L, Kaltreider RC, Ceriello A. Reactive oxygen species mediate a cellular ‘memory’ of high glucose stress signalling.  Diabetologia. 2007;  50 1523-1531
    CrossrefPubMedGoogle Scholar
  • 32 Marfella R, D'Amico M, Esposito K, Baldi A, Filippo C Di, Siniscalchi M, Sasso FC, Portoghese M, Cirillo F, Cacciapuoti F, Carbonara O, Crescenzi B, Baldi F, Ceriello A, Nicoletti GF, D'Andrea F, Verza M, Coppola L, Rossi F, Giugliano D. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.  Diabetes. 2006;  55 622-632
    CrossrefPubMedGoogle Scholar
  • 33 Hoeldtke RD, Bryner KD, MacNeill DR, Hobbs GR, Baylis C. Peroxynitrite versus nitric oxide in early diabetes.  Am J Hypertens. 2003;  16 ((9 Pt 1)) 761-766
    CrossrefPubMedGoogle Scholar
  • 34 Vinik AI, Ullal J, Parson HK, Barlow PM, Casellini CM. Pioglitazone treatment improves nitrosative stress in type 2 diabetes.  Diabetes Care. 2006;  29 869-876
    CrossrefPubMedGoogle Scholar
  • 35 Nourooz-Zadeh J, Ziegler D, Sohr C, Betteridge JD, Knight J, Hothersall J. The use of pholasin as a probe for the determination of plasma total antioxidant capacity.  Clin Biochem. 2006;  39 55-61
    CrossrefPubMedGoogle Scholar
  • 36 Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and antioxi-dant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy.  Diabetes Care. 2004;  27 2178-2183
    PubMedGoogle Scholar
  • 37 Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N. SNK-860 Diabetic Neuropathy Study Group . Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.  Diabetes Care. 2001;  24 1776-1782
    PubMedGoogle Scholar
  • 38 Sima AA, Calvani M, Mehra M, Amato A. Acetyl-L-Carnitine Study Group . Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials.  Diabetes Care. 2005;  28 89-94
    CrossrefPubMedGoogle Scholar
  • 39 Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.  Diabetes Care. 2006;  29 68-72
    CrossrefPubMedGoogle Scholar
  • 40 Vinik AI, Tuchman M, Safirstein B, Corder C, Kirby L, Wilks K, Quessy S, Blum D, Grainger J, White J, Silver M. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies.  Pain. 2007;  128 169-179
    CrossrefPubMedGoogle Scholar
  • 41 Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, Bastyr 3rd EJ, Wolka AM, Vinik AI. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.  Diabetes Care. 2007;  30 896-902
    CrossrefPubMedGoogle Scholar

The authors declare that there are no conflicts of interest.

Correspondence

Prof. U. JuliusMD 

Medizinische Klinik und Poliklinik III

Universitaetsklinikum Dresden

Fetscherstr. 74

01307 Dresden

Germany

Phone: +49/351/458 23 06

Fax: +49/351/458 53 06

Email: ulrich.julius@uniklinikum-dresden.de

      >